Crossmark

The first human clinical study for NMN has started in Japan

Crossref DOI link: https://doi.org/10.1038/npjamd.2016.21

Published Online: 2016-10-27

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tsubota, Kazuo https://orcid.org/0000-0002-8874-7111
License Information

Text and Data Mining valid from 2016-10-27

Version of Record valid from 2016-10-27
More Information

Article History

First Online: 27 October 2016

Competing interests

: The author has applied for a Japanese patent titled ‘Therapeutic agent, ameliorative agent or preventive of corneal failure’, Number: PCT/JP2016/062452.